Know Cancer

or
forgot password

Phase II Study of Antineoplastons A10 and AS2-1 Capsules With Total Androgen Blockade in Patients With Stage III or IV Adenocarcinoma of the Prostate


Phase 2
18 Years
N/A
Not Enrolling
Both
Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer

Thank you

Trial Information

Phase II Study of Antineoplastons A10 and AS2-1 Capsules With Total Androgen Blockade in Patients With Stage III or IV Adenocarcinoma of the Prostate


OBJECTIVES:

- Determine the antitumor activity of antineoplastons A10 and AS2-1 capsules in
combination with total androgen blockade in patients with localized, regional or
metastatic adenocarcinoma of the prostate by determining the proportion of patients who
experience an objective tumor response.

- Evaluate the adverse effects of and tolerance to this regimen in these patients.

OUTLINE: This is an open-label study.

Patients receive gradually escalating doses of antineoplastons A10 and AS2-1 capsules orally
6-7 times daily until the maximum tolerated dose is reached. Treatment continues for at
least 3 months in the absence of disease progression or unacceptable toxicity. Concurrently,
patients continue hormonal therapy with flutamide, leuprolide, or bicalutamide at the same
dose as before beginning antineoplaston therapy.

Tumors are measured every 4 months for 2 years, every 6 months for 2 years, and then
annually for 2 years.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically proven localized, regional, or metastatic adenocarcinoma of the
prostate

- Progressive disease during prior hormonal therapy (both antiandrogen and
gonadotropin-releasing hormone) and must continue hormonal therapy

- Measurable tumors or tumor markers

- Bone metastases allowed

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- Karnofsky 60-100%

Life expectancy:

- At least 3 months

Hematopoietic:

- WBC at least 3,000/mm^3

- Platelet count at least 100,000/mm^3

Hepatic:

- No hepatic failure

- Bilirubin no greater than 2.5 mg/dL

- SGOT no greater than 2 times normal

Renal:

- No chronic renal failure

- BUN less than 60 mg/dL

- Creatinine no greater than 2.5 mg/dL OR

- Creatinine clearance greater than 60 mL/min

- Blood ammonia normal

Cardiovascular:

- No severe heart disease

Pulmonary:

- No severe lung disease

Other:

- Fertile patients must use effective contraception during and for 4 weeks after study
participation

- No serious active infections or fever

- No other prior or concurrent second malignancy within the past 2 years

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- At least 4 weeks since prior biologic therapy and recovered

Chemotherapy:

- At least 4 weeks since prior chemotherapy and recovered

Endocrine therapy:

- See Disease Characteristics

Radiotherapy:

- At least 4 weeks since prior radiotherapy and recovered

Surgery:

- Not specified

Other:

- At least 4 weeks since prior investigational clinical trial

- No other concurrent treatment for metastatic prostate cancer

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Principal Investigator

Stanislaw R. Burzynski, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Burzynski Research Institute

Authority:

United States: Federal Government

Study ID:

CDR0000066560

NCT ID:

NCT00003517

Start Date:

Completion Date:

Related Keywords:

  • Adenocarcinoma of the Prostate
  • Stage III Prostate Cancer
  • Stage IV Prostate Cancer
  • Recurrent Prostate Cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Prostatic Neoplasms

Name

Location

Burzynski ClinicHouston, Texas  77055-6330